GB2479153B - The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy - Google Patents

The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy

Info

Publication number
GB2479153B
GB2479153B GB1005364.3A GB201005364A GB2479153B GB 2479153 B GB2479153 B GB 2479153B GB 201005364 A GB201005364 A GB 201005364A GB 2479153 B GB2479153 B GB 2479153B
Authority
GB
United Kingdom
Prior art keywords
cbdv
epilepsy
treatment
phytocannabinoid
cannabidivarin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1005364.3A
Other versions
GB2479153A (en
GB201005364D0 (en
Inventor
Benjamin Whalley
Claire Williams
Gary Stephens
Takashi Futamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Original Assignee
GW Pharma Ltd
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd, Otsuka Pharmaceutical Co Ltd filed Critical GW Pharma Ltd
Priority to GB1005364.3A priority Critical patent/GB2479153B/en
Publication of GB201005364D0 publication Critical patent/GB201005364D0/en
Priority to TW100108735A priority patent/TWI583374B/en
Priority to ARP110101014 priority patent/AR080730A1/en
Priority to NZ60292511A priority patent/NZ602925A/en
Priority to EP11712658A priority patent/EP2552430A1/en
Priority to CN201180026947.4A priority patent/CN103025325B/en
Priority to KR1020127028091A priority patent/KR101849703B1/en
Priority to US13/075,873 priority patent/US9125859B2/en
Priority to SG2012070793A priority patent/SG184236A1/en
Priority to JP2013501945A priority patent/JP5918748B2/en
Priority to MX2012011033A priority patent/MX2012011033A/en
Priority to SG10201502480XA priority patent/SG10201502480XA/en
Priority to EP20194696.9A priority patent/EP3763361B1/en
Priority to AU2011234225A priority patent/AU2011234225B2/en
Priority to MYPI2012004222A priority patent/MY162129A/en
Priority to CA2794620A priority patent/CA2794620C/en
Priority to EA201290975A priority patent/EA036044B1/en
Priority to PCT/GB2011/050649 priority patent/WO2011121351A1/en
Priority to BR112012024480A priority patent/BR112012024480A8/en
Publication of GB2479153A publication Critical patent/GB2479153A/en
Priority to IL222132A priority patent/IL222132B/en
Priority to ZA2012/08141A priority patent/ZA201208141B/en
Application granted granted Critical
Publication of GB2479153B publication Critical patent/GB2479153B/en
Priority to US14/685,753 priority patent/US10799467B2/en
Priority to AU2016244223A priority patent/AU2016244223A1/en
Priority to AU2018217303A priority patent/AU2018217303A1/en
Priority to US17/012,448 priority patent/US12023305B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1005364.3A 2010-03-30 2010-03-30 The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy Active GB2479153B (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GB1005364.3A GB2479153B (en) 2010-03-30 2010-03-30 The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TW100108735A TWI583374B (en) 2010-03-30 2011-03-15 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
ARP110101014 AR080730A1 (en) 2010-03-30 2011-03-28 USE OF CANABIDIVARINE PHYTOCHANABINOID (CBDV) IN THE TREATMENT OF EPILEPSY
MYPI2012004222A MY162129A (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
EA201290975A EA036044B1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
CN201180026947.4A CN103025325B (en) 2010-03-30 2011-03-30 The purposes of plant cannabinoids cannabidivarin CBDV Cannabidivarol (CBDV) in treatment epilepsy
KR1020127028091A KR101849703B1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
US13/075,873 US9125859B2 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
SG2012070793A SG184236A1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
JP2013501945A JP5918748B2 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivine (CBDV) in the treatment of epilepsy
MX2012011033A MX2012011033A (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy.
SG10201502480XA SG10201502480XA (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
EP20194696.9A EP3763361B1 (en) 2010-03-30 2011-03-30 Cannabidivarin (cbdv) for use in the treatment of epilepsy
AU2011234225A AU2011234225B2 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
NZ60292511A NZ602925A (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
CA2794620A CA2794620C (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
EP11712658A EP2552430A1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
PCT/GB2011/050649 WO2011121351A1 (en) 2010-03-30 2011-03-30 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
BR112012024480A BR112012024480A8 (en) 2010-03-30 2011-03-30 USE OF THE PHYTOCANABINOID CANNABIDIVARIN (CBDV) IN THE TREATMENT OF EPILEPSY
IL222132A IL222132B (en) 2010-03-30 2012-09-24 Use of cannabidivarin for the preparation of medicaments for treating epilepsy or epileptic seizures
ZA2012/08141A ZA201208141B (en) 2010-03-30 2012-10-29 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
US14/685,753 US10799467B2 (en) 2010-03-30 2015-04-14 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
AU2016244223A AU2016244223A1 (en) 2010-03-30 2016-10-11 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
AU2018217303A AU2018217303A1 (en) 2010-03-30 2018-08-17 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
US17/012,448 US12023305B2 (en) 2010-03-30 2020-09-04 Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1005364.3A GB2479153B (en) 2010-03-30 2010-03-30 The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy

Publications (3)

Publication Number Publication Date
GB201005364D0 GB201005364D0 (en) 2010-05-12
GB2479153A GB2479153A (en) 2011-10-05
GB2479153B true GB2479153B (en) 2014-03-19

Family

ID=42228625

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1005364.3A Active GB2479153B (en) 2010-03-30 2010-03-30 The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy

Country Status (1)

Country Link
GB (1) GB2479153B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
EP1811983B1 (en) 2004-11-16 2020-10-07 GW Pharma Limited New use for cannabinoid
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (en) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
GB2487183B (en) * 2011-01-04 2018-10-03 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
EP3062774A2 (en) * 2013-10-31 2016-09-07 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EP3067058A1 (en) 2015-03-13 2016-09-14 Farmagens Health Care Srl Biological composition based on engineered lactobacillus paracasei subsp. paracasei f19 for the biosynthesis of cannabinoids
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
JP2019524655A (en) 2016-06-29 2019-09-05 キャンサイエンス イノベーションズ インコーポレーテッドＣａｎｎｓｃｉｅｎｃｅ Ｉｎｎｏｖａｔｉｏｎｓ Ｉｎｃ． Decarbonized cannabis resin, its use, and process for producing it
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064109A2 (en) * 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
GB2434312A (en) * 2006-01-18 2007-07-25 Gw Pharma Ltd Cannabinoid extracts for treating neurodegeneration
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064109A2 (en) * 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
GB2434312A (en) * 2006-01-18 2007-07-25 Gw Pharma Ltd Cannabinoid extracts for treating neurodegeneration
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neurology, vol. 62, 2004, pages 2095-2097 *

Also Published As

Publication number Publication date
GB2479153A (en) 2011-10-05
GB201005364D0 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
GB2479153B (en) The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
ZA201208141B (en) Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
GB2471565B (en) Use of tetrahydrocannabivarin (THCV) in the treatment of epilepsy
PT2709604T (en) Cannabidivarin for use in the treatment of neuropathic pain
GB2487183B (en) Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
GB2499174B (en) Self-contained patient monitor
EP2596741A4 (en) Endoscope, and treatment instrument for endoscope
PL2652193T3 (en) Treatment
EP2629736A4 (en) Tissue treatment
GB201120345D0 (en) Medical console
EP2626000A4 (en) Endoscope adapter, endoscope processor, and endoscope system
EP2740419A4 (en) Treatment instrument
GB201004172D0 (en) Skin treating device
EP2621498A4 (en) Combination treatment for dermatological conditions
EP2621497A4 (en) Combination treatment for rosacea
EP2521569A4 (en) Combined treatment utilizing vb-201
EP2796082A4 (en) Illuminating unit for endoscope, and endoscope
HRP20180011T1 (en) Compounds for use in the treatment of filariasis
GB201013573D0 (en) Treatment
PL2536400T3 (en) Medicament comprising myramistin
TWM402712U (en) Rescue wheelchair
PL2456445T3 (en) Agent for the treatment of skin conditions
GB201014097D0 (en) Treatment
EP2545858A4 (en) Surgical retractor
GB2477546B (en) Skin treatment apparatus

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20230323 AND 20230329